New book by Larry Connors Click here Improve your trading - See how
Stock Profiler welcomes investors to chat LIVE about these stocks and more on their upgraded website with FREE Investor Tools, Live Chats, and much more! Sign up now at www.stockprofiler.us. Companies who want to broadcast their message are encouraged to contact Stock Profiler.US, LLC at (603) 424-4420.
-------------------------------------------
Ryder System, Inc. (NYSE: R | Quote | Chart | News | PowerRating) closed at $63.48 Thursday, trading 1,115,800 shares.
Company News- September 5, 2008 : Ryder Named One of Top 50 Companies for Latinas by LATINA Style Magazine
LATINA Style Magazine has named Ryder System, Inc. (NYSE: R | Quote | Chart | News | PowerRating) to the 2008 LATINA Style 50, recognizing Ryder as one of the top 50 companies for Latinas to work for in the United States. This is Ryder's eighth time to appear on the list, which has been published for 11 years.
To read the full news release, go to www.stockprofiler.us, and click the Headline link after entering the ticker symbol.
About LATINA Style Magazine
LATINA Style broke new ground in 1994 by launching the first national magazine dedicated to the needs and concerns of the contemporary Latina professional working woman and the Latina business owner in the United States. With a national circulation of 150,000 and a readership of nearly 600,000, LATINA Style is unique in its ability to reach both the seasoned professional and the young Latina entering the workforce for the first time. LATINA Style's culturally sensitive editorial environment showcases Latina achievements in all areas, including business, science, civic affairs, education, entertainment, sports, and the arts.
About Ryder
Ryder provides leading-edge transportation, logistics and supply chain management solutions worldwide. Ryder's stock (NYSE: R | Quote | Chart | News | PowerRating) is a component of the Dow Jones Transportation Average and the Standard & Poor's 500 Index. Ryder ranks 371st on the FORTUNE 500 and 1,631st on the Forbes Global 2000. For more information on Ryder System, Inc., visit www.ryder.com.
-------------------------------------------
Cytokinetics, Incorporated (NASDAQ: CYTK | Quote | Chart | News | PowerRating) closed at $4.96 Thursday, trading 87,100 shares.
Company News- September 5, 2008 : Cytokinetics Announces the Initiation of Third Phase IIa Clinical Trial of CK-1827452
Cytokinetics, Incorporated (NASDAQ: CYTK | Quote | Chart | News | PowerRating) announced earlier today the initiation of its third Phase IIa clinical trial evaluating CK-1827452, a novel cardiac myosin activator being developed by the company for the potential treatment of patients with either acutely decompensated or chronic heart failure. CK-1827452 is the subject of a Collaboration and Option Agreement between Cytokinetics and Amgen Inc.
To read the full news release, go to www.stockprofiler.us, and click the Headline link after entering the ticker symbol.
About Cytokinetics
Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that may address areas of significant unmet clinical needs. Cytokinetics' cardiovascular disease program is focused to cardiac myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics' lead compound from this program, CK-1827452, a novel small molecule cardiac myosin activator, entered Phase II clinical trials for the treatment of heart failure in 2007. Under a strategic alliance established in 2006, Cytokinetics and Amgen Inc. are performing joint research focused on identifying and characterizing activators of cardiac myosin as back-up and follow-on potential drug candidates to CK-1827452. Amgen has obtained an option for an exclusive license to develop and commercialize CK-1827452, subject to Cytokinetics' development and commercial participation rights. Cytokinetics' cancer program is focused on mitotic kinesins, a family of motor proteins essential to cell division. Under a strategic alliance established in 2001, Cytokinetics and GlaxoSmithKline (GSK) are conducting research and development activities focused on the potential treatment of cancer. Cytokinetics is developing two novel drug candidates that have arisen from this program, ispinesib and SB-743921, each a novel inhibitor of kinesin spindle protein (KSP), a mitotic kinesin. Cytokinetics is sponsoring a Phase I/II clinical trial of ispinesib as monotherapy as a first-line treatment in chemotherapy-nave patients with locally advanced or metastatic breast cancer. In addition, Cytokinetics is conducting a Phase I/II trial of SB-743921 in patients with non-Hodgkin or Hodgkin lymphomas. GSK has obtained an option for the joint development and commercialization of ispinesib and SB-743921. Cytokinetics and GSK are conducting collaborative research activities directed to the mitotic kinesin centromere-associated protein E (CENP-E). GSK-923295, a CENP-E inhibitor, is being developed under the strategic alliance by GSK; GSK began a Phase I clinical trial with GSK-923295 in 2007. In April 2008, Cytokinetics announced the selection of a potential drug candidate directed towards skeletal muscle contractility which may be developed as a potential treatment for skeletal muscle weakness associated with neuromuscular diseases or other conditions. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.
-------------------------------------------
The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Stock Profiler.US, LLC's News Division, which includes but is not limited to www.stockprofiler.us, www.associatesfortune.com, www.businessnetwire.us, www.fastmoneytalk.com, www.markettelegraph.com, www.thewallstreetleader.com, financialbusinessnews.us and www.daytradersdigest.com. Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers and terms of use, go to www.stockprofiler.us.
Keywords: Small Cap Investments, Investor Relations, I/R Services, Investment Tools, Stock Profiles, Stock Market Quotes News, Media Coverage
CONTACT: www.stockprofiler.us e-mail: info@stockprofiler.us Tel: +1 603 424 4420 WWW: http://www.stockprofiler.us
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
